GeneDx Holdings (WGS) Stock

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14, 2025, the compensation committee of GeneDx's board of directors granted a total of 69,089 restricted stock units (“RSUs”) to three newly-hired employees as inducements material to each employee entering into employment with GeneDx. The foregoing includes 37,497 RSUs granted to Bryan Dechairo, as an indu.

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts include the NICU market expansion and pediatric neurology diagnostics, supported by faster turnaround times, non-invasive testing, and EHR integration. Financial improvements include a 44% revenue increase, higher reimbursement rates, and improved gross margins, positioning GeneDx favorably among its peers.

GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.

Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children's Hospital, was conducted on nearly 187,000 samples performed and a.

GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of genetic conditions. The company's Q3 earnings led to a >50% uplift in the share price this week, with ~$287 revenues pledged for 2024, and a gross margin of >60%.

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Association, published peer-reviewed research from the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, the largest study of its kind to explore the utility of whole genome sequencing (WGS) to identify 255 early onset genetic conditions in newborns from a diverse populatio.

GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarter performance exceeded expectations, driven by over 125% year-over-year growth in its whole exome and genome business, now 74% of total revenue. GeneDx reduced its quarterly cash burn significantly and anticipates profitability by 2025, with increasing reimbursement rates and expanding Medicaid coverage boosting revenue.